Daily Derm Times: April 8, 2025

To stay up-to-date with the latest dermatology news, sign up to receive our eNewsletters.

Championing Patient and Consumer Safety in Dermatology

Dermatology Times' Editor in Chief Christopher Bunick, MD, PhD, discusses patient safety in the wake of AAD 2025, focusing on BPO recalls, corticosteroid risks, and JAK inhibitor innovations.

Alphyn Doses First Patient in Phase 2b Trial for Zabalafin Hydrogel

Alphyn Biologics has dosed the first patient in a global phase 2b trial of zabalafin hydrogel for mild to moderate atopic dermatitis.

Deep Learning Tool Differentiates Keloids From Malignant Lesions Without Dermoscopy

After fine-tuning, the VGG16 convolutional neural network outperformed other deep learning models in 2 of 3 key classification tasks.

Abrocitinib Shows Promise as a Therapy for Netherton Syndrome

A new case report demonstrated the JAK inhibitor’s efficacy at improving disease severity up to 6 months.

Dupilumab Shows No APO Risk During Pregnancy

Compared to untreated patients, dupilumab-treated women showed no increased risk for spontaneous abortion, gestational diabetes, or hypertensive disorders.

Oxymetazoline 1% Cream Reduces Erythema in Patients with Rosacea

The product was safe and effective after 4 weeks of topical use, specifically on patients with darker skin types.

Kesty Redness Scale Enhances Analysis of Facial Erythema, Study Reports

The Kesty Redness Scale offers a validated, easy-to-use tool to reliably assess facial redness in clinical dermatology.